About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). | Stereotactic ablative body radiotherapy SABR combined with immunotherapy L19-IL2 versus standard of care in stage IV NSCLC patients ImmunoSABR A multicentre randomised controlled openlabel phase II trial